基于新发明的猪瘟疫苗C株感染性cDNA克隆高效病毒拯救技术平台(专利申请号：201510052888.8)，用牛病毒性腹泻病毒(BVDV)基因组非编码区(3′UTR、5′UTR)、抗原蛋白(Erns、E2)和复制调控相关非结构蛋白(NS2-3、NS5B)单独替换或联合替换CSFV C株基因组对应区域，在猪源细胞系(SK6、PK15)上拯救、筛选重组嵌合病毒CSFV/BVDV，在细胞(体外)和机体(体内)水平研究各种重组嵌合病毒的生长特性、组织细胞嗜性、遗传稳定性和致病性及其分子基础；猪体接种研究重组病毒机体感染后体内的动态分布和分泌病毒能力，分析重组病毒接种诱导猪体免疫应答的水平和规律，筛选获得能在猪源细胞上高效增殖，对猪完全无毒力，不具有水平传播能力，能诱导猪体抵抗CSFV强毒株致死感染和携带血清学鉴别诊断标记的重组嵌合病毒，为发展用于猪瘟预防和根除的新型标记(DIVA)疫苗奠定基础。

Based on the infectious cDNA clone of the CSFV vaccine strain C, the terminal untranslated region (3′UTR, 5′UTR), the antigenic glycoproteins (Erns, E2) and/or non-structure proteins (NS2-3, NS5B) genes of classical swine fever virus (CSFV) were replaced by the analogous sequence of bovine viral diarrhoea virus (BVDV) to generate a series of chimeric CSFV/BVDV full-length DNA copies. The recombinant chimeric viruses were recovered from SK6 or PK15 cells transfected directly with the chimeric DNA copies. Growth, cell tropism, virulence, immunogenicity and genetic stability of the chimeric viruses were investigated both in cells in vitro and in infected pigs in vivo. Antibody response profiles induced by chimeric viruses in infected pigs were evaluated by ELISA assays. Chimeric CSFV/BVDV viruses with vaccine properties and serological markers of differentiation between infected and vaccinated animals (DIVA) were obtained. These studies are contributive to understand the structure and function of pestiviral genomes and to develop genetically modified DIVA vaccines for CSF prevention and eradication.